[Usefulness of determining the blood levels of B-type natriuretic peptide in the evaluation of cardiotoxicity in children treated with anthracyclines]
- PMID: 17317907
[Usefulness of determining the blood levels of B-type natriuretic peptide in the evaluation of cardiotoxicity in children treated with anthracyclines]
Abstract
Cardiotoxicity of anthracydines is a serious clinical problem, and it is the main factor limiting their wide use, despite the recognized antineoplastic properties of anthracyclines. Early detection of adverse effects of anthracyclines is therefore very important for proper prevention of congestive heart failure. Current methods of detection of cardiotoxic activity of anthracyclines (ECG, ECHO) are suitable only for fully symptomatic cases. In subclinical damage of the heart these methods are insufficient. Measurement of NT-proBNP has been shown to be a sensitive indicator of cardiac abnormalities. Concentration of NT-proBNP in blood increases very early in response to volume overload of the ventricles of the heart seen in congestive heart failure. Chemical and physical features of NT-proBNP: long half-time in blood, low requirements for sample collection and storage conditions and easy availability of kits for its measurements make NT-proBNP a very good marker of subclinical postanthracycline congestive heart failure.
Similar articles
-
N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.J Pediatr Hematol Oncol. 2007 Jul;29(7):440-4. doi: 10.1097/MPH.0b013e3180640d42. J Pediatr Hematol Oncol. 2007. PMID: 17609620
-
Cardiac biomarkers indicate a need for sensitive cardiac imaging among long-term childhood cancer survivors exposed to anthracyclines.Acta Paediatr. 2015 Mar;104(3):313-9. doi: 10.1111/apa.12862. Epub 2014 Dec 10. Acta Paediatr. 2015. PMID: 25393922 Clinical Trial.
-
Assessment of anthracycline-induced cardiotoxicity with biochemical markers.Exp Oncol. 2007 Dec;29(4):309-13. Exp Oncol. 2007. PMID: 18199989
-
Cardiac toxicity after anthracycline chemotherapy in childhood.Herz. 2000 Nov;25(7):676-88. doi: 10.1007/pl00001982. Herz. 2000. PMID: 11141677 Review.
-
Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines.Cancer Treat Rev. 2004 Nov;30(7):643-50. doi: 10.1016/j.ctrv.2004.06.002. Cancer Treat Rev. 2004. PMID: 15531396 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials